Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134(38): 1879-1888
DOI: 10.1055/s-0029-1237528
DOI: 10.1055/s-0029-1237528
CME-Beitrag | Review article
Hämatologie/Onkologie
© Georg Thieme Verlag KG Stuttgart · New York
Notfälle in der Hämatologie und Onkologie
Emergencies in hematology and oncologyFurther Information
Publication History
eingereicht: 26.3.2009
akzeptiert: 25.6.2009
Publication Date:
10 September 2009 (online)
Schlüsselwörter
Tumorhyperkalzämie - Hyperviskositätssyndrom - Tumorlysesyndrom - Vena-cava-superior-Syndrom - maligner Perikarderguss
Keywords
tumor associated hypercalcemia - hyperviscosity syndrome - tumor lysis syndrome - Vena-cava-superior syndrome - malignant pericardial effusion
Literatur
- 1 Annemans L, Moeremans K, Lamotte M. et al . Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries. Leuk Lymphoma. 2003; 44 77-83
- 2 Armstrong B A, Perez C A, Simpson J R, Hederman M A. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987; 13 531-539
- 3 Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost. 2007; 33 350-354
- 4 Body J J. Hypercalcemia of malignancy. Semin Nephrol. 2004; 24 48-54
- 5 Böhme A, Ruhnke M, Karthaus M. et al . Therapie von Pilzinfektionen in der Hämatologie und Onkologie. Leitlinien der Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO). Dtsch Med Wochenschr. 2001; 126 1440-1447
- 6 Buchheidt D, Böhme A, Cornely O. et al . Dokumentierte Infektionen bei Neutropenie - Empfehlungen zu Diagnostik und Therapie. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie - Fachgruppe der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr. 2001; 126 1085-1090
- 7 Cairo M S. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 2002; 3 (Suppl 1) S26-S31
- 8 Cairo M S, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127 3-11
- 9 Clines G A, Guise T A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer. 2005; 12 549-583
- 10 Coiffier B, Altman A, Pui C H, Younes A, Cairo M S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26 2767-2778
- 11 Dequanter D, Lothaire P, Berghmans T, Sculier J P. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 2008; 15 3268-3271
- 12 Dimopoulos M A, Kyle R A, Anagnostopoulos A, Treon S P. Diagnosis and management of Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005; 23 1564-1577
- 13 Halfdanarson T R, Hogan W J, Moynihan T J. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc. 2006; 81 835-848
- 14 Higdon M L, Higdon J A. Treatment of oncologic emergencies. Am Fam Physician. 2006; 74 1873-1880
- 15 Karam N, Patel P, deFilippi C. Diagnosis and management of chronic pericardial effusions. Am J Med Sci. 2001; 322 79-87
- 16 Karatolios K, Maisch B. Die Perikardbiopsie. Dtsch Med Wochenschr. 2007; 132 1707-1710
- 17 Kremer R, Shustik C, Tabak T, Papavasiliou V, Goltzman D. Parathyroid-hormone-related peptide in hematologic malignancies. Am J Med. 1996; 100 406-411
- 18 Kunitoh H, Tamura T, Shibata T. et al . A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009; 100 464-469
- 19 Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003; 29 467-471
- 20 Ostler P J, Clarke D P, Watkinson A F, Gaze M N. Superior vena cava obstruction: a modern management strategy. Clin Oncol (R Coll Radiol ). 1997; 9 83-89
- 21 Parish J M, Marschke Jr R F, Dines D E, Lee R E. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc. 1981; 56 407-413
- 22 Roodman G D. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23 435-441
- 23 Stewart A F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352 373-379
- 24 Thomas L, Kwok Y, Edelman M J. Management of paraneoplastic syndromes in lung cancer. Curr Treat Options Oncol. 2004; 5 51-62
- 25 Uaje C, Kahsen K, Parish L. Oncology emergencies. Crit Care Nurs Q. 1996; 18 26-34
- 26 Urruticoechea A, Mesia R, Dominguez J. et al . Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer. 2004; 43 209-214
- 27 Van Poznak C. Hypercalcemia of malignancy remains a clinically relevant problem. Cancer J. 2006; 12 21-23
- 28 Wilkes J D, Fidias P, Vaickus L, Perez R P. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Cancer. 1995; 76 1377-1387
- 29 Wilson L D, Detterbeck F C, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007; 356 1862-1869
- 30 Zarkovic M, Kwaan H C. Correction of hyperviscosity by apheresis. Semin Thromb Hemost. 2003; 29 535-542
Priv.-Doz. Dr. med. Roland Schroers
Medizinische Klinik, Universitätsklinikum
Bochum, Knappschaftskrankenhaus Bochum Langendreer
In
der Schornau 23–25
44892 Bochum
Phone: 0234/299-83447
Fax: 0234/299-3459
Email: R.Schroers@web.de